
Early findings suggest linvoseltamab could be a useful new option for new multiple myeloma patients | ASH 2025
Early results from the LINKER-MM1 trial show high response rates for linvoseltamab, offering new hope for newly diagnosed patients.
Robert Orlowski, M.D., Ph.D., shared the early effectiveness results from the phase 1 part of the LINKER-MM1 trial. He said the overall response rate was very high, and many patients had deep responses, even at this early stage of treatment.
He also discussed how linvoseltamab could fit into care for newly diagnosed patients. With several treatment options already available, he said linvoseltamab may become another strong choice, especially for patients who cannot receive other drugs or who may benefit from a targeted approach.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.






















































